Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
14.11. | TriSalus Reports Q3 2024 Financial Results and Provides Business Update | 56 | Business Wire | DENVER--(BUSINESS WIRE)--TriSalus Life Sciences Inc., (Nasdaq: TLSI), an oncology company integrating novel delivery technology with immunotherapy to transform treatment for patients with liver... ► Artikel lesen | |
14.11. | TriSalus Life Sciences, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
14.11. | TriSalus Life Sciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
13.11. | A Look Ahead: TriSalus Life Sciences' Earnings Forecast | 2 | Benzinga.com | ||
TRISALUS LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
01.11. | TriSalus Life Sciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
26.10. | TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Consensus Rating of "Buy" by Analysts | 2 | MarketBeat | ||
25.10. | Northland initiates TriSalus shares with outperform, cites sales growth | 3 | Investing.com | ||
25.10. | Northland stuft TriSalus-Aktien mit "Outperform" ein und verweist auf Umsatzwachstum | 1 | Investing.com Deutsch | ||
26.09. | TriSalus Life Sciences adds oncology expert to SAB | 1 | Investing.com | ||
26.09. | TriSalus Life Sciences erweitert wissenschaftlichen Beirat um Onkologie-Experten | 1 | Investing.com Deutsch | ||
23.09. | TriSalus reports breakthrough in liver tumor treatment | 2 | Investing.com | ||
16.09. | TriSalus vor Verdopplung? Oppenheimer prognostiziert starkes Kurswachstum | 2 | Investing.com Deutsch | ||
16.09. | Oppenheimer initiates TriSalus stock at outperform on liver cancer opportunity | - | Investing.com | ||
16.09. | Oppenheimer stuft TriSalus-Aktie mit "Outperform" ein aufgrund von Chancen in der Leberkrebs-Behandlung | 10 | Investing.com Deutsch | ||
13.09. | TriSalus Life Sciences CEO buys $75k in company stock | 1 | Investing.com | ||
13.09. | TriSalus Life Sciences CEO buys $24,850 in company stock | 1 | Investing.com | ||
10.09. | Trisalus Life Sciences director sells shares worth $49 | 1 | Investing.com | ||
16.08. | TriSalus stock holds Buy rating with $11 target | 1 | Investing.com | ||
15.08. | TriSalus Life Sciences GAAP EPS of -$0.21, revenue of $7.4M | 1 | Seeking Alpha | ||
15.08. | TriSalus Life Sciences, Inc. - 8-K, Current Report | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ASTRIA THERAPEUTICS | 8,950 | -1,65 % | Astria TherapeuticS GAAP EPS of -$0.42 in-line | ||
ROCKET LAB USA | 20,900 | +9,20 % | Is Rocket Lab Stock a Millionaire Maker? | ||
BOIRON | 29,500 | +0,68 % | BOIRON: EVOLUTION OF GOVERNANCE | July 3rd, 2024
The Board of Directors of Laboratoires BOIRON, meeting today under the chairmanship of Thierry BOIRON, has enacted an evolution of the Group's governance.
In this context, Thierry... ► Artikel lesen | |
HARROW | 43,775 | +3,15 % | Pre-market Movers: California BanCorp, Harrow, Inc., Quantum Computing, BTC Digital, Calidi Biotherapeutics | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.15 A.M. ET).In the Green California BanCorp. (BCAL) is up over 33% at $23.01.
Quantum... ► Artikel lesen | |
MEDICINOVA | 1,700 | 0,00 % | MediciNova, Inc.: MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders | LA JOLLA, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen | |
ESSA PHARMA | 1,790 | +2,58 % | ESSA Pharma: NBC-Anlegerclub feiert schnelle +23% Rendite! | Der No Brainer Club (NBC) hat erneut sein Gespür für unterbewertete Biotech-Perlen unter Beweis gestellt. Mit ESSA Pharma konnten Mitglieder in diesem fulminanten Biotech-Herbst innerhalb weniger Tage... ► Artikel lesen | |
AQUESTIVE THERAPEUTICS | 4,590 | -3,06 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update | Anaphylm (epinephrine) Sublingual Film pre-NDA meeting scheduled for fourth quarter 2024AQST-108 (epinephrine) Topical Gel pre-IND meeting scheduled for fourth quarter 2024Libervant® (diazepam) Buccal... ► Artikel lesen | |
SHINECO | 2,470 | -1,59 % | SHINECO, INC. - 10-Q, Quarterly Report | ||
CYANOTECH | 0,260 | 0,00 % | Cyanotech Reports Financial Results for the Second Quarter and First Six Months of Fiscal 2025 | KAILUA KONA, Hawaii--(BUSINESS WIRE)--Cyanotech Corporation (OTCQB: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results... ► Artikel lesen | |
REVIVA PHARMACEUTICALS | 1,190 | -2,46 % | Reviva Pharmaceuticals: Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial - - Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine's improvement on negative... ► Artikel lesen | |
CUMBERLAND PHARMACEUTICALS | 1,080 | -3,57 % | Cumberland Pharma-Aktie erreicht 52-Wochen-Tief bei 1,07 US-Dollar | ||
LYRA THERAPEUTICS | 0,189 | +6,29 % | Lyra Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary | ||
NUTRIBAND | 4,400 | -3,51 % | Nutriband, Inc.: Nutriband Inc. Issued Full Patent from the Chinese National Intellectual Property Administrant for Its "Abuse and Misuse Deterrent Transdermal System" Application | ORLANDO, FL / ACCESSWIRE / October 31, 2024 / Nutriband (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced that theChinese National Intellectual Property Administrant (CNIPA) has fully issued its patent titled... ► Artikel lesen | |
BAYER | 19,518 | -0,13 % | Bayer: Shortseller am Werk - das war haarscharf | Am Mittwoch hat die Aktie von Bayer ihren Kursverfall nach Zahlen vom Vortag nahtlos fortgesetzt. Auf der Handelsplattform Xetra knickte der DAX-Wert um weitere 3,5 Prozent ein. Aus charttechnischer... ► Artikel lesen | |
MERCK KGAA | 138,30 | +0,14 % | Merck: Solide Zahlen | Merck KGaA lässt den Durchhänger nach dem Corona-Boom weiter hinter sich. Auch im vergangenen Quartal sorgte ein sich in Teilen erholendes Geschäft mit Halbleitermaterialien beim Dax-Konzern für Auftrieb... ► Artikel lesen |